First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

NCT04993443 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

40

Enrollment

OTHER

Sponsor class

Stopped Copmeletion of Part A SAD cohorts, sponsor cancelled Part B-D cohorts

Conditions

Asthma

Interventions

DRUG: LQ036
OTHER: Matching Placebo

Sponsor

Syneos Health

Collaborators

[object Object]